About Taste receptor type 2 member 30
Taste receptor type 2 member 30 (TAS2R30) is a protein
from Homo sapiens identified by UniProt accession
P59541, 319 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Taste receptor type 2 member 30 |
| UniProt accession | P59541 |
| Gene | TAS2R30 |
| Organism | Homo sapiens |
| Length | 319 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (12)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.22
- lung adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.16
- sensory perception of bitter taste · score 0.15
- head and neck squamous cell carcinoma · score 0.13
- blood protein measurement · score 0.11
- gastric adenocarcinoma · score 0.10
- actinic keratosis · score 0.06
- sebaceous of Jadassohn nevus · score 0.06
- squamous cell carcinoma · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P59541-F1 | alphafold | PREDICTED | 85.35 | — |
Amino-acid sequence (319 residues)
MITFLPIIFS ILIVVIFVIG NFANGFIALV NSIEWVKRQK ISFVDQILTA LAVSRVGLLW VLLLHWYATQ LNPAFYSVEV RITAYNVWAV TNHFSSWLAT SLSMFYLLRI ANFSNLIFLR IKRRVKSVVL VILLGPLLFL VCHLFVINMD ETVWTKEYEG NVTWKIKLRS AMYHSNMTLT MLANFVPLTL TLISFLLLIC SLCKHLKKMQ LHGKGSQDPS TKVHIKALQT VTSFLLLCAI YFLSMIISVC NFGRLEKQPV FMFCQAIIFS YPSTHPFILI LGNKKLKQIF LSVLRHVRYW VKDRSLRLHR FTRGALCVF
Explore Taste receptor type 2 member 30 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets